Intramuscular and intratumoral DNA-based delivery of checkpoint-inhibiting antibodies enable significant efficacy despite distinct exposure

This abstract was selected by our Scientific Committee to pitch on the programme in the R2B session (PM).

This abstract is not published by request of the author.

Authors

Organisations

Presenting author

Liesl Jacobs, PhD student, Laboratory for Therapeutic and Diagnostic Antibodies, KU Leuven- University of Leuven
liesl.jacobs@kuleuven.be
Contact us now
REGISTER AS A DELEGATE NOW

Flanders.bio Strategic Partners

Flanders.bio Supporting Partners